Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced that Dr. Alastair Leighton has joined as Chief Operating Officer (COO). With almost three decades in the biopharma industry working at leading global pharmaceutical companies, Dr. Leighton brings a wealth of experience in manufacturing, supply chain operations and commercial strategy.
“I’m excited to welcome Alastair to Chemify to help us with building and scaling our ability to make complex molecules on demand at scale for our partners using Chemputation,” said Dr. Lee Cronin, CEO of Chemify. “His expertise with large biopharmaceutical organizations will help us continue to meet the strong demand for consistent, reproducible small molecule development.”
Also Read: Stardust Power Appoints Chris Celano as COO
Prior to joining Chemify, Dr. Leighton was senior vice president of manufacturing and supply at MeiraGTx, where he was responsible for establishing end-to-end manufacturing and supply chain capabilities for the commercial-stage gene therapies. He also held several roles during his tenure at GlaxoSmithKline, including vice president and site director. Additionally, Dr. Leighton was senior director of supply chain operation and programs at Crucell, which is part of Johnson & Johnson. Prior to Crucell, he held several roles at Novartis, including segment head, new primary operations and new primary operations start-up leader for their vaccines manufacturing facility. Dr. Leighton holds a BSc in Physics from the University of Sheffield and a PhD in Electrical Engineering from the University of Manchester.
“Chemify is uniquely positioned to disrupt the industry through its AI, digital chemistry and robotics platform that will not only optimize and expedite the discovery of novel molecules, but accelerate the availability of life-saving treatments for patients,” said Dr. Leighton, COO of Chemify. “I’m excited to work with Lee and the team to scale Chemify’s operational capabilities and meet the unmet customer demand for the design and synthesis of complex small molecules and innovative new drugs.”
SOURCE: Businesswire